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Abstract 
Hypertension among young people is common, affecting 1 in 8 adults aged between 20 and 
40 years. This number is likely to increase with lifestyle behaviors and lowering of 
hypertension diagnostic thresholds. Early life factors influence blood pressure (BP) although 
the mechanisms are unclear; BP tracks strongly within individuals from adolescence through 
to later life. Higher BP at a young age is associated with abnormalities on heart and brain 
imaging and increases the likelihood of cardiovascular events by middle age. However, 
diagnosis rates are lower, and treatment is often delayed in young people. This reflects the 
lack of high-quality evidence that lowering BP in young adults improves cardiovascular 
outcomes later in life.  
In this review we evaluate the current evidence regarding the association between BP in 
young adult life and adverse cardiovascular outcomes later in life. Following this, we discuss 
which young people with raised BP should be investigated for secondary causes of 
hypertension. Third, we assess the current models to assess cardiovascular risk and show a 
lack of validation in the younger age group. Fourth, we evaluate the evidence for lifestyle 
interventions in this age group and demonstrate a lack of persistence in BP lowering once 
the initial intervention has been delivered. Fifth, we address the pros and cons of drug 
treatment for raised BP in young people. Finally, there are unique life events in young 
people, such as pregnancy, that require specific advice on management and treatment of 
BP.  
Key words: 
Blood pressure, hypertension, young onset, young adult, cardiovascular outcomes, risk 
factor 
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Introduction 
Hypertension affects one quarter of the global population and is the leading modifiable risk 
factor for cardiovascular disease and mortality.1 Previously, treatment has tended to focus 
upon individuals in whom the 10-year risk of cardiovascular events is greatest, with 
increasing age being a strong factor. However, the presence of hypertension at a young age 
increases risk of cardiovascular events in middle age.2 It contributes to an earlier onset of 
coronary heart disease, heart failure, stroke and transient ischaemic attacks.3 While good 
national guidelines exist, they do not serve low-risk, young patients with hypertension as 
effectively as older patients. Furthermore, risk assessment is challenging in young patients 
due to limited validity and a focus upon systolic blood pressure that is less well correlated 
with cardiovascular end-points.2, 4  
 
The definition of “young” in guidelines varies as below the age of 50, 40 and 30 years.5-7 
Worldwide estimates of the prevalence of hypertension in the year 2000 amongst adults 
aged 20-29 were 12.7% in men and 7.4% in women rising to 18.4% and 12.6%, respectively, 
in 30-39 year olds.8  The estimated prevalence of hypertension among those aged 18-39 
years in the United States (2011-2012) was 7.3%.9 Both studies defined hypertension as an 
average blood pressure of greater than 140/90 mmHg or use of antihypertensive 
medication. More recently the definition of hypertension has been expanded by the 
American College of Cardiology/American Heart Association (ACC/AHA) 2017 guidelines to 
include blood pressure above 130/80 mmHg and thus the prevalence of hypertension by 
this criterion is likely far greater than that reported above.  Moreover, in selected 
populations the prevalence of hypertension may be even higher, for example African 
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Americans have a 2-fold higher risk of hypertension compared to whites as well as lower 
rates of blood pressure control.10  
 
Blood pressure in adulthood may also be determined by factors occurring many years 
earlier.11 Barker and colleagues proposed the Developmental Origins of Health and Disease 
hypothesis whereby the lifetime trajectory of BP is programmed in the perinatal period.12 
Whilst fetal growth restriction may play some role, other factors such as genetic and 
environmental influences are probably more significant.13 This is supported by studies 
demonstrating higher BP in adolescents whose mothers had experienced hypertensive 
disorders of pregnancy and higher rates of anti-hypertensive prescriptions to young adults 
born pre-term.14-16 Similarly, alterations in the cardiovascular system of those born 
prematurely or of low birth weight are well documented.17 Risk factors for young onset 
hypertension have been explored through several large studies (summarized in Table S1 
online supplement). 
 
Hypertension can have harmful health effects even at a young age. In the short-term it is 
associated with higher rates of left ventricular hypertrophy18 and alterations in brain volume 
and white matter hyperintensity volume, suggesting that hypertension in young adults may 
impact cardiovascular and brain health.19, 20 The Strong Heart Study assessed clinical and 
echocardiographic features in 1940 native Americans aged 14-39. Individuals with 
prehypertension (blood pressure 120 to 139/80 to 89 mmHg) and hypertension (blood 
pressure ≥140/90 or use of antihypertensive medications) had higher rates of left 
ventricular hypertrophy than normotensive individuals of the same age.18 In the long-term, 
multiple studies have demonstrated increased rates of cardiovascular disease and mortality 
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in young people with hypertension.2, 3, 21 Furthermore, blood pressure has been shown to 
strongly track with age meaning that individuals with elevated blood pressure in youth are 
likely to have elevated blood pressure in later life.11 Sundstrom et al. used data from 1.2 
million Swedish men (mean age 18 years) conscripted into military service between 1969 
and 1995 demonstrated a direct correlation between baseline blood pressure and 
cardiovascular mortality at follow up.2 The Coronary Artery Risk Development in Young 
Adults (CARDIA) longitudinal study has been important in exploring the contribution of early 
life risk factors to the development of coronary heart disease in later life using a cohort of 
5115 young adults in the United States aged 18-30.3, 22 They showed that elevated systolic 
blood pressure at baseline was more predictive of coronary artery calcium 15 years later 
than risk factor profile at point of follow up.22 Additionally a retrospective analysis of 
CARDIA data demonstrated a significantly higher risk of cardiovascular disease among 
hypertensives (defined by ACC/AHA 2017 guidelines) compared to normal blood pressure 
(<120/80 mmHg) in individuals below the age of 40 at baseline.3  
 
This shows the impact of early life risk factors upon long term health and implies that it may 
not be appropriate to defer addressing cardiovascular health until middle age. This is 
important because hypertensive patients below the age of 40 years have lower awareness, 
slower diagnosis rates and poorer blood pressure control than older individuals.9, 23, 24 A 
recent study identified wide-ranging barriers to good blood pressure control in young 
adults.25 These included psychosocial themes (e.g. concerns regarding the projection of a 
“sick-identity” upon young adults) and management concerns (e.g. appropriate drug 
treatment of women of childbearing potential). Many respondents were concerned about 
the benefits and risks of treatment, fear of misdiagnosis (and potential impact on life 
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insurance), adherence, follow up and resource allocation. These issues have been discussed 
extensively, with concerns expressed by primary care physicians that new national 
guidelines could lead to overdiagnosis and overtreatment.26, 27  
 
Defining blood pressure thresholds for hypertension in young people 
The American College of Cardiology/American Heart Association (ACC/AHA) lowered the 
diagnostic threshold for stage 1 hypertension in the 2017 Guidelines from 140/90 to 130/80 
mmHg across all age categories to some controversy, not least because it increased the 
prevalence of hypertension in the US population to 46%.7, 26, 28 This change in threshold was 
based on a systematic review of 10 studies,29 the largest of which was the Systolic Blood 
Pressure Intervention Trial (SPRINT) study.28  The mean age of participants in the systematic 
review ranged from 36 to 77 years with only one small study having a mean age at entry of 
less than 40 years and only four recruiting any participants aged under 50 years old.30 
 
Should we pay more attention to systolic or diastolic blood pressure in young people? 
Sundstrom et al. used data from 1.2 million Swedish men conscripted into military service 
between 1969 and 1995.2 All men underwent a medical at entry and blood pressure was 
recorded in a standardized way; there was a clear correlation between baseline blood 
pressure and cardiovascular mortality at follow up. Diastolic blood pressure was more 
strongly correlated to all-cause mortality than systolic blood pressure, with risk rising 
substantially above 90 mmHg. Hazard ratios were 1.02 (0.99-1.05) and 1.35 (1.26-1.45) 
respectively. Furthermore, diastolic hypertension is more common among patients under 
the age of 50 years (62.5% compared to 42% in over 50s).31 
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Additionally, there is uncertainty regarding the significance of isolated systolic hypertension 
in the young (systolic blood pressure ≥ 140 mmHg, diastolic blood pressure < 90mmHg). Less 
than 20% of untreated hypertensives below the age of 40 have isolated systolic 
hypertension, compared to 80% of over 50s.31  Isolated systolic hypertension in young 
people may represent increased pulse wave amplification rather than increased aortic 
stiffness, meaning that in many cases young adults with high brachial systolic pressures have 
normal central aortic pressure.32  However, McEniery et al. identified no difference in pulse 
wave amplification between isolated systolic hypertension patients and normotensives aged 
17 to 27 years, but demonstrated either increased stroke volume or increased aortic pulse 
wave velocity suggesting isolated systolic hypertension may not be a benign state in young 
people.33 More recently, Yano et al. noted among a cohort of 27,081 individuals from 
Chicago (mean age 33 ± SD 9 years, 39% hypertensive) that isolated systolic hypertension 
imparts increased risk of cardiovascular mortality compared to optimal blood pressure 
(<130/85 mmHg); adjusted hazard ratio for men was 1.23 (95% CI 1.03-1.46) and 1.55 for 
women (1.18-2.05).21 
 
Finally, a recent retrospective analysis of data derived from the  CARDIA study sought to 
identify whether young onset hypertensives defined using the 2017 ACC/AHA guidelines had 
increased cardiovascular events.3 This showed a higher rate of cardiovascular events for 
mildly elevated blood pressure (SBP 120-129mmHg, DBP <80mmHg) and stage 1 
hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg). However, all-cause mortality was 
not significantly elevated. 
 
 
MS ID: HYPE201913820  
 
9 
 
What is the optimal approach to high blood pressure in young adults? 
Broadly the management of young onset hypertension is the same as that of older 
individuals, but distinctions are made regarding investigation and referral strategies. Table 1 
sets out a summary of the American, European and British guidelines with respect to the 
management of hypertension in young adults. They differ in their classification of blood 
pressure and varied use of risk-based thresholds for treatment. We address 3 key questions: 
1. How should young adults with hypertension be investigated? 
Investigation in young adults is advocated across American, European and British guidelines 
for the identification of secondary causes of hypertension and evidence of organ damage.5-7 
Predictors of a secondary cause for hypertension include young age (<30 years) with no 
other risk factors, drug resistant hypertension, severe hypertension (>180/110 mmHg), 
sudden deterioration in blood pressure control, non-dipping status on ambulatory blood 
pressure monitoring or the presence of hypertension-mediated organ damage.34 
Recognizing secondary causes of hypertension is potentially beneficial, as this might direct 
specific treatment strategies and potentially cure high blood pressure in young patients. 
This is especially important in young people where the sustained duration of high blood 
pressure on organs such as the brain and kidneys may produce irreversible changes. 
Furthermore, the identification and treatment of secondary hypertension below the age of 
40 years is associated with better blood pressure control.35 
 
This beneficial impact needs to be balanced against the risks such as cost, patient burden, 
and incidental diagnoses from imaging investigations. Both the European and British 
guidelines state that secondary forms of hypertension are more common among young 
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adults with high blood pressure and more likely to be detected,5, 6 making a case to meet 
incurred costs through specific treatment gains. However, one study showed that young 
adults were less likely to have a recognized underlying cause than older patients, with 
prevalence ranging from 5.6% in the 18-29 age group, 8.1% in the 30-39 age group and 
17.4% in the over 70s.36  The most common causes of secondary hypertension among young 
adults were hypothyroidism (1.9%), renovascular disease (1.7%), renal insufficiency (1.5%), 
primary hyperaldosteronism (1.2%), Cushing’s syndrome (0.5%), and pheochromocytoma 
(<0.3%).  Renovascular disease was caused predominantly by fibromuscular dysplasia in 18-
29 year olds (89%) and atherosclerosis in 30-39 year olds (61%). 
 
 An electrocardiogram (ECG) is recommended to identify evidence of left ventricular 
hypertrophy alongside serum creatinine and microalbuminuria to evaluate for sub-clinical 
renal damage.5 However, ECG assessment has limited sensitivity for identifying left 
ventricular hypertrophy and therefore the European guidelines recommend an 
echocardiogram.6 Cardiac magnetic resonance imaging is more sensitive and specific than 
echo at identifying left ventricular hypertrophy and may be used to simultaneously evaluate 
for secondary causes of hypertension.37 Renal ultrasound and computerized tomography 
angiography are established modalities for screening for renal and renovascular disease.34 
 
2. Is a risk-based approach appropriate in young adults with hypertension? 
All three guidelines utilize 10-year cardiovascular models to provide thresholds for the 
initiation of antihypertensive therapy (Table 1). Basing treatment upon overall 
cardiovascular risk rather than specific blood pressure levels is supported by two meta-
analyses focused on cardiovascular risk reduction in middle-aged and older individuals.38, 39 
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However other authors have pointed to reports of overestimation of risk and lack of validity 
for using risk scores in this way.26, 27 Risk-based approaches can be problematic in the young 
because absolute 10-year cardiovascular risk is often low, irrespective of other risk factors, 
despite a substantially increased lifetime risk of cardiovascular events.  
 
In this respect the ACC/AHA guidelines are helpful as they advocate treating all stage 2 
hypertensives (SBP>140 and DBP>90 mmHg) regardless of 10-year cardiovascular risk.7 
When considering stage 1 hypertension (SBP 130-139 or DBP 80-89 mmHg) they advise 
treating those with atherosclerotic cardiovascular disease (ASCVD) estimated 10-year 
cardiovascular risk ≥ 10% or presence of diabetes or chronic kidney disease. However, the 
ASCVD risk score was validated on data derived from people aged 40-79 years so may be 
less applicable to younger patients.40 The European Guidelines for Cardiovascular Disease 
Prevention suggest the use of relative risk tables and heart age calculation (using the 
Systematic Coronary Risk Evaluation (SCORE) system).41 The validation window for SCORE is 
40 to 65 years and in contrast to the ASCVD which predicts mortality, SCORE assesses the 
risk of a first fatal atherosclerotic event.6 
 
The European guidelines highlight the lack of evidence for blood pressure lowering therapy 
in the young while acknowledging the epidemiological evidence of harm from higher blood 
pressure. Therefore, they suggest consideration of treatment to avoid more severe 
hypertension and the development of hypertension-mediated organ damage.6 In the UK, 
NICE recommends treatment of those with systolic blood pressure 140-159 mmHg or 
diastolic blood pressure 90-99 mmHg with evidence of target organ damage, or in those free 
of cardiovascular disease with a 10-year cardiovascular event risk of greater than 10%.5 In 
MS ID: HYPE201913820  
 
12 
 
the UK QRISK2® is the preferred 10-year risk assessment tool but was validated on 35-74 
year olds. 42 The latest version QRISK®3 has been extended to 25 to 84 years of age and 
includes relative risk, heart age and lifetime risk calculation.43  
 
3. How should young onset hypertension be treated? 
Epidemiological data suggests that blood pressure reduction at a population level is 
beneficial. The close tracking of blood pressure from early adulthood to later life and the 
finding of cardiovascular and brain changes in young adults with hypertension support the 
argument that young people with high blood pressure should be treated in the same way as 
older adults. However, there is an absence of data assessing pharmacological intervention in 
this young age group. Lifestyle interventions to address the risk factors are recommended.  
A recent systematic review and meta-analysis of 14 exercise studies in 18 to 40-year olds 
showed that supervised exercise programs improve clinic blood pressure by an average of 4-
5 mmHg at 3-6 month follow up, but the blood pressure lowering benefits were not 
sustained at 12 months.44  Furthermore, higher intensity programmes associated with 
greater than 4Kg weight loss had greater benefits.  Weight loss was found to have a greater 
impact on blood pressure compared to metoprolol treatment in young overweight patients 
(age less than 50 years).45 More research is required on how to sustain the short-term 
benefits of exercise, weight loss and other lifestyle interventions in this young population.  
 
Several meta-analyses have shown that thiazide diuretics, calcium channel antagonists, ACE 
inhibitors, angiotensin receptor blockers (ARB) and beta blockers are equally effective in 
reducing cardiovascular events in older individuals and “younger” individuals below the age 
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of 65 years.46 47 48 This finding is reflected across the European and ACC/AHA hypertension 
guidelines that do not advocate a specific starting agent out of those drug classes. NICE, in 
contrast, advocates an aged-based algorithm whereby an ACE inhibitor or ARB is 
recommended first line for those below 55 years except for people of black African or 
African-Caribbean family origin in whom calcium channel antagonists are recommended.5 
The reason for this age-based approach is due to two crossover studies that pointed to 
individuals below the age of 55 being more responsive to ACE inhibitors and beta blockers 
than calcium channel antagonists and diuretics. 49 50 Where pharmacological management is 
indicated, clinicians should consider ethnicity, gender and comorbidity (in keeping with 
older individuals).  
 
Whilst national guidelines do not recommend different treatment of men and women, it is 
important to consider pregnancy potential in women for several reasons. Firstly, poor 
control of chronic hypertension during pregnancy increases the risk of pre-eclampsia and 
good blood pressure control prior to pregnancy is beneficial.51  Secondly, ACE inhibitors and 
ARBs in women of childbearing age should be avoided during pregnancy due to risk of 
adverse fetal outcomes.6, 52 Those already taking ACE inhibitors or ARBs should be 
counselled of the fetal risks in pregnancy and consider switching to alternative anti-
hypertensives such as labetalol, nifedipine or methyl dopa if they are planning to conceive.52  
It is also important to consider that up to 50% of pregnancies are unplanned so ACE 
inhibitors and ARBs should be withdrawn promptly upon awareness of pregnancy and 
alternative agents offered.  
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What are the gaps in evidence? 
This review has identified a number of areas where more evidence is needed to guide 
clinicians who manage young people with hypertension. Whilst it is clear that high blood 
pressure in young adults has important detrimental consequences in later life, there is very 
limited evidence whether interventions can reduce the risk of cardiovascular events or 
adverse changes in brain structure. Randomized controlled trials of interventions are 
urgently needed to answer this question as the number of young adults world-wide with 
hypertension increases. Progress has been made to make risk scores more relevant to young 
adults, including the use of lifetime risk and heart age scores. Diastolic blood pressure may 
be important to include in risk assessment. However, a change from 10-year cardiovascular 
risk to lifetime risk would have implications for the number of people becoming eligible for 
intervention. The risks and benefits of this approach need to be explored further. How this is 
best communicated to improve shared decision making and increase persistence of lifestyle 
changes over time also warrants further investigation. As a previously untreated cohort of 
young adults with hypertension are offered pharmacological interventions, we are still not 
sure whether the drugs that are effective in older people are as efficacious in young people. 
Therefore, studies comparing different treatment strategies in young onset hypertension 
are needed.  
 
Conclusions 
Young-onset hypertension is a common condition that increases all-cause mortality and 
results in subclinical organ damage early in its natural history. Epidemiological studies 
suggest that early life factors are important and should be addressed by public health 
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policies to reduce cardiovascular disease later in life. Although higher blood pressure in 
young people tracks with blood pressure later in life and is associated with adverse short- 
and medium-term cardiovascular outcomes, the absence of randomized trials of blood 
pressure lowering in young adults means the safety and efficacy of anti-hypertensive 
therapy in mild grades of hypertension are unknown.  
 
Referral of selected patients to secondary care (Table 2) is suggested as it permits more 
detailed assessment, evaluation of subclinical organ damage and investigation of secondary 
causes of hypertension (Table 3). This can allow more personalized management given the 
limitations of current risk-based approaches in this population. However, care needs to be 
taken to avoid overdiagnosis and overtreatment. Early intervention with medication in 
young mild hypertensives (blood pressure > 140/90 mmHg) free of cardiovascular disease 
could be considered following a one-year trial of lifestyle modification. Given the 
uncertainty in this group of patients, shared decision making is crucial, involving patients, 
primary care physicians and specialists. 
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Table 1: ACC/AHA, ESC and NICE(UK) Guidelines for the management of hypertension with 
special emphasis on care of young patients 
Office Blood 
Pressure 
120-
129/<80 
SBP 130-139 or 
DBP: 80-89 
SBP ≥ 140 or 
DBP ≥ 90 
BP ≥ 160-179 
/100-109 
SBP ≥ 180 or 
DBP ≥ 110 
Classification 
ACC/AHA 
(2017) 
Elevated Stage 1 Stage 2 Stage 2 Stage 2 
ESC (2018) - High Normal Grade 1 Grade 2 Grade 3 
NICE NG136 
(2019) 
- - Stage 1 Stage 2 Severe 
Treatment Threshold 
ACC/AHA 
(2017) 
Lifestyle Treat if CVD or a 
10-year ASCVDi 
risk > 10% 
Treat  Treat  Treat 
ESC (2018) - Lifestyle advice 
but treat if high 
risk. 
Low-mod 
risk: Treat if 
lifestyle fails.  
High risk: 
Treat 
Treat Treat 
NICE NG136 
(2019)  
- - OD/CVD, 
diabetes or 
10-year CV 
Treat Treat 
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risk > 10%  
Specialist Referral 
ACC/AHA 
(2017) 
Suspected secondary HTN particularly primary aldosteronism 
ESC (2018) Suspected secondary HTN. Follow up of hypertensive emergencies. 
Resistant HTN. Detailed assessments of organ damage.  
NICE NG136 
(2019) 
Accelerated HTN (≥ 180/110) with papilledema or retinal hemorrhages, 
Suspected secondary HTN 
Considerations for young patients 
ACC/AHA 
(2017) 
Young = <30 years. Consider screening for primary aldosteronism. Optimal 
point of intervention is not clear. 
ESC (2018) Refer under 40s with grade 2 HTN or greater. Treatment of uncomplicated 
grade I HTN “may be considered prudent”. Unclear whether ISH should be 
treated.  
NICE NG136 
(2019) 
Young onset hypertension is <40. Risks are underestimated.  Refer to 
allow detailed assessment of organ damage. ISH to be treated as per older 
individuals. 
SBP: Systolic Blood Pressure, DBP: Diastolic blood pressure, ABPM: Ambulatory blood 
pressure monitoring, HBPM: Home blood pressure monitoring, CVD:  Cardiovascular 
disease, ASCVD: Atherosclerotic cardiovascular disease. OD: Organ Damage ISH: Isolated 
systolic hypertension. HTN: hypertension 
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Table 2: Indications to refer young onset hypertension to secondary care 
 Age < 30 years with no risk factors 
 Resistant hypertension 
 Sudden deterioration in BP control 
 Evidence of end organ damage 
 Clinical features or investigations suggesting a secondary cause of hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Summary of recommendations for young adults with hypertension 
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 Public health policy to optimize fetal and early life health 
 Lifestyle modifications to improve risk profile including physical activity 
 BP threshold to consider intervention at 140/90 mmHg 
 Arrange ambulatory BP monitoring 
 Assess for end organ damage and secondary causes by measuring renal function, 
thyroid function, microalbuminuria and ECG 
 Echocardiogram if abnormal ECG or finding of LVH would alter treatment 
 Refer selected patients to secondary care for further assessment (Table 2) 
 If starting drug treatment in females, consider pregnancy potential 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legends: 
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Figure 1. Summary of Review of Young Onset Hypertension 
 

Investigation and treatment of high blood pressure in young 
people. Too much medicine or appropriate risk reduction? 
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Supplemental Table S1: Association between  risk factors and outcome in young onset 
hypertension 
 
Risk factor Association between risk factor and outcome Ref 
Greater subscapular skin 
fold 
↑incidence of BP ≥165/90 mmHg or anti-HTN 
treatment over 8 year FU (aged 20-49 years) 
1  
Greater waist 
circumference 
↑incidence of BP ≥138/85 mmHg or anti-HTN 
treatment over 10 year FU 
2 
BMI ↑BMI in young-onset HTN (BP ≥140/90mmHg before 
40 years) versus NTN men  
3 
Greater 24-hour sodium 
excretion 
↑ SBP in 20-59-year-old men and women (NTN and 
HTN) 
4 
Low sodium diet ↓SBP at 30 day follow up (aged ≤ 45 years) 5 
Greater meat 
consumption 
↑incidence of BP ≥135/85 mmHg or anti-HTN 
treatment over 15 year FU 
6 
Greater plant food 
consumption 
↓incidence of BP ≥135/85 mmHg or anti-HTN 
treatment over 15 year FU 
6 
Greater alcohol 
consumption 
Alcohol consumption not associated with incidence of 
BP ≥140/90 mmHg or anti-HTN treatment over 20 year 
follow up. In European American women, there was 
reduced HTN risk in current but not former drinkers 
7 
Greater serum 
carotenoid concentration 
↓incidence of BP ≥140/90 mmHg or anti-HTN 
treatment over 20 year FU 
8 
Greater folate 
consumption 
↓incidence of BP ≥140/90 mmHg or anti-HTN 
treatment over 20 year FU 
9 
 6 
 
 
Greater serum 
triglycerides 
↑serum triglycerides in young-onset HTN (BP 
≥140/90mmHg before 40 years) versus NTN 
3 
Greater fasting insulin ↑incidence of BP ≥140/90 mmHg or anti-HTN 
treatment over 20 year FU 
10 
Greater serum urate ↑incidence of BP ≥140/90 mmHg or anti-HTN 
treatment over 20 year FU 
11 
Greater C-reactive 
protein 
↑incidence of BP ≥140/90 mmHg, history of HTN, or 
anti-HTN medication over 8 year follow up but not 
significant when BMI accounted for 
12 
Increased level of 
physical activity 
↓incidence of BP ≥140/90 mmHg or anti-HTN 
medication over 15 years 
13 
Greater depression score ↑incidence of BP ≥160/95 mmHg or anti-HTN 
treatment over 5 years, significant in black but not 
white participants when analysis conducted separately 
14 
Personality traits 
(greater hostility and 
impatience) 
↑incidence of BP ≥140/90 mmHg or anti-HTN 
treatment over 15 years, but not significant in all sex-
race groups when analysis conducted separately 
15 
Lower socioeconomic 
status  
↑incidence of BP ≥140/90 mmHg or anti-HTN 
treatment over 10 years 
16 
BP: Blood Pressure, NTN: Normotension, HTN: Hypertension, BMI: Body Mass Index, 
SBP: Systolic BP, FU: Follow Up. Study populations were NTN and aged 18-30 years at 
baseline, and included both men and women, unless stated otherwise. 
